Anyone else following SLS heading into the end of the year? My interest comes down to three things: patients still receiving GPS years into treatment, an approaching Phase 3 survival analysis, and a second AML drug with encouraging clinical data. SELLAS is developing galinpepimut-S, or GPS, a therapeutic cancer vaccine licensed from Memorial Sloan Kettering. It targets WT1, a protein expressed by leukemia cells. The aim is to teach the immune system what to recognize after treatment has put the
CryptoAlerta — análise de criptomoedas e mercado em tempo real